NOVARTIS N (NOT MU) stock market data APIs
€102.3807
0(0%)
as of September 17, 2025
Try our APIs with
free plan!
NOVARTIS N Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NOT.MU.
Prev. Close
102.3807
Open
102.3807
High
102.3807
Low
102.3807
52 wk Range
71.4774-110.98
Market Cap
160 075 M
Dividends (Yield)
0.0488
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVARTIS N data using free add-ons & libraries
Get NOVARTIS N Fundamental Data
NOVARTIS N Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVARTIS N News
New
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Novartis (NVS) been one of those stocks this year? A quick gl...
INCY Announces New Late-Stage Data on Skin Disease Drug
Incyte INCY announced new 24-week interim data from the STOP-HS program on pipeline candidate, povorcitinib (INCB54707), in adult patients with moderate to severe hidradenitis suppurativa (HS). The d...
Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
Shares of clinical-stage biotech Monte Rosa Therapeutics GLUE rose 44% on Monday after announcing that it had entered into a collaboration deal with pharma giant Novartis NVS to develop novel molecula...
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
Monte Rosa Therapeutics GLUE shares soared 44.1% in the last trading session to close at $6.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This c...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
